Citeline Podcasts

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DBDTTSHFXNBTVLT6PE4MX45B74/

本期《中国生物技术播客》聚焦康方生物的依沃西单抗将如何改写历史，以及在PD-(L)1/VEGF双抗之间是否即将发生国内头对头三期临床试验。 Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?

Scrip Senior Writer Joseph Haas interviewed attorneys Kevin Cooper and Bill Roegge of Cooley LLC about recent events and trends in biopharmaceutical merger-and-acquisition activity. They discussed the current state of M&A after a busy conclusion to the first quarter and how that interplays with financing and partnering activity. In addition, Kevin offered tips for smaller companies to get good outcomes when dealing with large pharma firms, Bill talked about whether 2026 may be a year of competing bids in biopharma M&A and the discussion closed with a look at deals centered on platform technologies and their potential to replenish an acquirer's pipeline.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Icotyde或将成为强生史上最重磅产品；daraxonrasib数据助力Revolution；Travere的Filspari成为首个用于治疗FSGS的药物；GSK重金押注B7-H4抗体药物偶联物；以及礼来夺得全球制药销售额榜首。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KROBJCLAKVFBLCZ7BGBGCE3VDQ/

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 17, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Icotyde could be J&J’s biggest ever product; daraxonrasib data boost Revolution; Travere’s Filspari becomes first drug for FSGS; GSK bets big on B7-H4 antibody-drug conjugate; and Lilly grabs top spot in global pharma sales. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KROBJCLAKVFBLCZ7BGBGCE3VDQ/

Generics Bulletin senior reporter Urtė Fultinavičiūtė speaks to Medicines for Europe’s director general Adrian van den Hoven about pertinent environmental regulation changes in the region.

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs discuss potential takeaways from the Trump Administration floating ophthalmologist, entrepreneur and Fox News contributor Houman David Hemmati as the next potential Center for Biologics Evaluation and Research director (:34), as well as the appointment of US Food and Drug Administration Principal Deputy Commissioner Sara Brenner to a position in the Health and Human Services Department (8:30). They also consider whether the FDA’s approach to adding an indication for leucovorin could be more widely used in the rare disease space (14:08) and new guidance for the agency’s plausible mechanism pathway (22:50). #pharma #business More On These Topics From The Pink Sheet New CBER Director Candidate Could Signal Industry Cred Important Again: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/new-cber-director-candidate-could-signal-industry-cred-important-again-ZDJ4ECR4QNDBPBRTKNHD2B5R24/ US FDA’s Principal Deputy Commissioner Moving To HHS As Senior Counselor For Public Health: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-principal-deputy-commissioner-moving-to-hhs-as-senior-counselor-for-public-health-C64ZB6WRTNEJ7MC7I3ZY3KNP6I/ US FDA’s Literature-Based Leucovorin Approval May Offer A Rare Disease Template: https://insights.citeline.com/pink-sheet/rare-diseases/us-fdas-literature-based-leucovorin-approval-may-offer-a-rare-disease-template-Z34IYMFF35ENVJXV4N4ZT4GG6Q/ US FDA To Clarify Plausible Mechanism Framework With Genome Editing Guidances, Workshop: https://insights.citeline.com/pink-sheet/advanced-technologies/cell-and-gene-therapies/us-fda-to-clarify-plausible-mechanism-framework-with-genome-editing-guidances-workshop-QTWKR3NCXJFJNKCOE3BTBSW4K4/

김윤철 삼성바이오에피스 상무는 Scrip과의 인터뷰에서 ADC 및 기타 신약개발 전략 등에 대해 이야기했습니다. 이 기사를 요약한 내용입니다. (AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다) Story link: https://insights.citeline.com/scrip/focus-on-asia/south-korea/samsung-bioepis-sharpens-differentiation-strategy-as-global-adc-market-matures-T4E7D2U4DZFJFIERGRWM7PECTM/

Join Scrip and The Pink Sheet's Tokyo-based team Lisa Takagi and Ian Haydock for a roundup of key commercial and policy/regulatory developments in Japan's biopharma market over the first few months of this year, including some important corporate divestments and new product approvals. Also a look at how the Iran war is impacting the healthcare sector in the country.

How can small biotechs tap billion‑dollar AI models without giving up their data? David Wild talks with Eli Lilly's Aliza Apple about Lilly TuneLab, a federated learning platform that lets companies use Lilly’s in-house drug discovery models while keeping their IP and datasets fully private. They dive into early use cases in ADMET and antibody developability, what early-stage users actually do in their first 90 days, and how shared models could reshape the economics of drug R&D.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 特朗普政府对部分药品及原料药征收100%关税；美国关税政策给获美批准的中国药品带来阴影； 吉利德收购Tubulis；深入解析Neurocrine对Soleno的收购要约；以及对第一季度并购活动的分析。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-O7KEIWGMHBCLZBHKJPKGHOZYPE/

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Trump’s 100% tariffs and pharma; US tariffs loom over US-approved Chinese drugs; Gilead’s Tubulis buy-out; a closer look at Neurocrine’s Soleno bid; and an analysis of Q1 M&A. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-O7KEIWGMHBCLZBHKJPKGHOZYPE/

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman and Editor-in-Chief Nielsen Hobbs discuss the details of the US Food and Drug Administration’s labeling update for leucovorin (:41), including GSK’s subsequent move to re-withdraw the application (19:45). They also grade the tenure of Steve Ubl as he prepares to leave as Pharmaceutical Research and Manufacturers of America president and CEO (21:02) and consider what the organization may seek in its next leader (27:07). #pharma #business More On These Topics From The Pink Sheet A Regulatory Pathway Of One: US FDA’s Wellcovorin Approval Would Be Hard To Scale: https://insights.citeline.com/pink-sheet/rare-diseases/a-regulatory-pathway-of-one-us-fdas-wellcovorin-approval-would-be-hard-to-scale-BHEAMFMG5BDJHJY5K6Z5OJF22A/ Outgoing PhRMA CEO Ubl Fought, Shaped Policies and Politics Around Price Controls: https://insights.citeline.com/pink-sheet/r-and-d/breaking-phrma-ceo-steve-ubl-leaving-later-this-year-2FNX2D5LE5GC3J2HARTZPHZDB4/

Israel has been a prolific source of biotech and AI-driven startups for years, but can it compete as a strategic R&D partner for global pharma? Mati Gill, CEO of AION Labs, makes the case that it can. AION's venture studio model brings together AstraZeneca, Merck KGaA, Pfizer and Teva under one roof to co-create AI-native drug discovery companies, and its portfolio is already producing results: CombinAbleAI, one of its startups, was acquired by insitro less than two years after it was founded. Gill talks about Israel's genuine strengths in science and technology, the structural gaps that still need closing, and why three years of operating through an active war may actually be a point in the ecosystem's favour for risk-conscious partners. Recorded, with some interruptions, from Tel Aviv.

Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme. #clinicalstrategy #oncology

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来收购Centessa的意义；Apellis为Biogen注入新能力；中国企业在肥胖症领域取得的快速进展；口服药物在肥胖症治疗中占据主导地位；以及全球制药研发管线规模的缩减。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HFN7H2ELQBBRHHFQQ2AYFBMXNM/

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HFN7H2ELQBBRHHFQQ2AYFBMXNM/

In this episode of the China biopharma English-language podcast, Xu Hu talks about recently China releasing two guidelines related to CAR-T therapies within a month and the strategic position that the country puts its cell therapy sector. The Pink Sheet stories related to this episode: CAR-T Guidelines Signal China’s Next Phase Of Cell Therapy Regulatory System Building CAR-Ts Win Big In New China Drug Coverage Lists

A legal firm’s perspective on how the UK should evolve its medtech regulatory system, global harmonization and opportunities to embed best practice AI.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年3月27当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 默克公司力推Terns及其他交易；勃林格殷格翰对欧洲创新环境不佳的警示；科伦与默克的协议如何改变了中国的交易格局；神经科学研发重振旗鼓；以及美国新的低密度脂蛋白胆固醇（LDL-C）指南与药物成本。